Engineered Myeloma Models Reveal Spatial Tumor–Stroma Dependencies

  • Engineered myeloma models (GEMM/CDX) with spatial transcriptomics to resolve tumor microenvironment architecture
  • Targeted NSD2 degradation disrupts supportive niches and reprograms myeloma–stroma signaling in situ
  • Model-guided framework to rank combinations and de-risk translation for next-gen multiple myeloma therapies